| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
- Nitric oxide (NO) production (IC50 = 25.6 ± 1.8 μM) [1]
- Nuclear factor-κB (NF-κB) p65 [1] - Mitogen-activated protein kinases (MAPKs): ERK1/2, JNK, p38 [1] - Inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2) [1] - Tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) [1] |
|---|---|
| ln Vitro |
- 7,3',4'-Tri-O-methylluteolin (also known as 5-hydroxy-3′,4′,7-trimethoxyflavone) exhibited dose-dependent inhibitory activity against LPS-induced NO production in RAW 264.7 macrophages, with an IC50 value of 25.6 ± 1.8 μM. At 50 μM, it inhibited NO production by 78.3 ± 3.2% compared to the LPS-treated model group [1]
- It significantly reduced LPS-induced secretion of pro-inflammatory cytokines: at 50 μM, TNF-α levels were decreased by 67.5 ± 4.1%, and IL-6 levels by 72.8 ± 3.8% [1] - The compound downregulated LPS-induced iNOS and COX-2 expression at both protein and mRNA levels. At 50 μM, iNOS protein expression was reduced by 69.2 ± 3.5%, COX-2 protein by 71.6 ± 3.3%; iNOS mRNA by 65.4 ± 4.0%, COX-2 mRNA by 68.9 ± 3.7% [1] - It inhibited LPS-induced nuclear translocation of NF-κB p65, reducing the nuclear fraction of p65 by 58.7 ± 3.6% at 50 μM [1] - 7,3',4'-Tri-O-methylluteolin suppressed LPS-induced phosphorylation of MAPKs (ERK1/2, JNK, p38) by 52.3 ± 3.4%, 56.8 ± 3.9%, and 60.1 ± 4.2% respectively at 50 μM [1] - It showed no significant cytotoxicity to RAW 264.7 macrophages at concentrations up to 100 μM, with cell viability maintained above 90% [1] - In silico molecular docking analysis revealed that the compound binds to the active site of NF-κB p65 with a binding energy of -7.8 kcal/mol, and to COX-2 with a binding energy of -8.2 kcal/mol [1] |
| Enzyme Assay |
- NO production assay: RAW 264.7 macrophages were seeded in 96-well plates and pretreated with 7,3',4'-Tri-O-methylluteolin (12.5, 25, 50 μM) for 1 h, then stimulated with LPS for 24 h. The supernatant was mixed with Griess reagent, incubated at room temperature for 15 min, and absorbance was measured at 540 nm to quantify NO levels. IC50 value was calculated from dose-response curves [1]
- Pro-inflammatory cytokine assay: Cells were treated as above, and supernatant was collected. TNF-α and IL-6 concentrations were quantified by enzyme-linked immunosorbent assay (ELISA) following standard procedures [1] - Western blot assay for protein expression: Cells were pretreated with the compound (25, 50 μM) for 1 h, stimulated with LPS for 24 h (for iNOS/COX-2) or 30 min (for MAPKs/NF-κB p65). Cells were lysed, nuclear and cytoplasmic fractions were separated (for p65), proteins were resolved by SDS-PAGE, transferred to membranes, and probed with specific antibodies. Band intensities were quantified by densitometry [1] - RT-PCR assay for mRNA expression: Total RNA was extracted from treated cells, reverse-transcribed to cDNA. PCR amplification was performed with specific primers for iNOS, COX-2, TNF-α, IL-6, and GAPDH (internal control). Amplified products were analyzed by agarose gel electrophoresis, and band intensities were quantified [1] - In silico molecular docking: The 3D structure of the compound was constructed and minimized. Crystal structures of targets (NF-κB p65, COX-2) were retrieved from protein data banks. Docking was performed using appropriate software, and binding energy, hydrogen bonds, and hydrophobic interactions were analyzed to evaluate binding affinity [1] |
| Cell Assay |
- Cell viability assay: RAW 264.7 macrophages were seeded in 96-well plates (5×10³ cells/well) and incubated overnight. 7,3',4'-Tri-O-methylluteolin (12.5, 25, 50, 100 μM) was added, and cells were cultured for 24 h. A cell viability reagent was added, incubated for 4 h, and absorbance was measured at 570 nm to assess cytotoxicity [1]
- Inflammatory response assay: Cells were seeded in 6-well plates (2×10⁵ cells/well) and allowed to adhere overnight. They were pretreated with the compound (12.5, 25, 50 μM) for 1 h, then stimulated with LPS for 24 h (for cytokine/NO detection) or specified time points (for protein/mRNA analysis). Samples (supernatant, cells, RNA) were collected for subsequent assays [1] |
| References | |
| Additional Infomation |
It has been reported that 5-hydroxy-3',4',7-trimethoxyflavone exists in Veratrum dahuricum, Salvia euphratica and other organisms with relevant data.
- 7,3',4'-tri-O-methylluteolin is a flavonoid compound with the chemical structure 5-hydroxy-3',4',7-trimethoxyflavone[1] - Its anti-inflammatory mechanism involves inhibiting the NF-κB signaling pathway (blocking p65 nuclear translocation) and the MAPK pathway (inhibiting ERK1/2, JNK, p38 phosphorylation), thereby downregulating the expression of pro-inflammatory cytokines (TNF-α, IL-6) and enzymes (iNOS, COX-2)[1] - Computer simulations have confirmed that it has a good binding affinity to key inflammatory targets (NF-κB p65, COX-2), supporting its anti-inflammatory effect. In vitro anti-inflammatory activity [1] - This compound shows potential as a natural anti-inflammatory agent because it effectively inhibits LPS-induced macrophage inflammation without significant cytotoxicity [1] |
| Molecular Formula |
C18H16O6
|
|---|---|
| Molecular Weight |
328.3160
|
| Exact Mass |
328.094
|
| CAS # |
29080-58-8
|
| PubChem CID |
5272653
|
| Appearance |
White to yellow solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
536.3±50.0 °C at 760 mmHg
|
| Flash Point |
197.0±23.6 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.606
|
| LogP |
3.22
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
24
|
| Complexity |
490
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
HIXDQWDOVZUNNA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H16O6/c1-21-11-7-12(19)18-13(20)9-15(24-17(18)8-11)10-4-5-14(22-2)16(6-10)23-3/h4-9,19H,1-3H3
|
| Chemical Name |
2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~20 mg/mL (~60.92 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2 mg/mL (6.09 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0458 mL | 15.2290 mL | 30.4581 mL | |
| 5 mM | 0.6092 mL | 3.0458 mL | 6.0916 mL | |
| 10 mM | 0.3046 mL | 1.5229 mL | 3.0458 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
